Clinical trial NCT03915795: Statins Study in Kawasaki Disease Children With Coronary Artery Abnormalities
Official title: Application of Statins in Long-term Treatments of Kawasaki Disease Complicated With Severe Coronary Artery Abnormalities in Children
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Kawasaki Disease
Coronary Artery Abnormalities
Keywords: Kawasaki Disease
coronary artery abnormalities
statins
Lead sponsor: Children's Hospital of Fudan University
Sponsor class: OTHER
First posted: 2019-04-16
Enrollment: 30
Sex: ALL
Minimum age (years): 2
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The KD children admitted to the Cardiology ward in Children's Hospital of Fudan University, Shanghai, China

Brief summary: The aim of this study is to investigate the effects of statins on chronic inflammation, coronary artery abnormalities and clinical cardiac events in long-term KD children complicated with severe coronary artery abnormalities, and the feasibility and safety of statins in treatment of KD children.

Detailed description: Kawasaki disease (KD) is an acute self-limited vasculitis and occurs almost exclusively in childhood. It predominantly affects medium-sized arteries, most commonly the coronary arteries. Although the use of intravenous immunoglobulin (IVIG) has obviously decreased the incidence of coronary arteries (CA) abnormalities, still a part of KD children occur CA abnormalities, even medium, large or giant aneurysms. The coronary aneurysms can develop to thrombus and arterial stenosis, which may cause severe cardiac events, for example, myocardial infarction. It is the main cause of disability and death in KD children. Now KD has been the leading cause of acquired heart disease in children.

Some studies found that ongoing vascular chronic inflammation and oxidative stress persisted in the long-term KD vasculopathy. Endothelial dysfunction, increased stiffness, and intima-media thickening have been noted in both affected coronary arteries and systemic arteries. Statins (hydroxymethylglutaryl coenzyme-A reductase inhibitors) not only are a kind of drug lowering low-density lipoprotein cholesterol, but also have been reported to have potentially beneficial pleiotropic effects on inflammation, endothelial function, oxidative stress, platelet aggregation, coagulation, and fibrinolysis. They have been the cornerstone of therapy for the primary and secondary prevention of atherosclerotic cardiovascular events in adults. In recently years, statins have been considered to be used in KD children with coronary aneurysms. Several short-term small studies in such patients treated with statins have shown reductions in high-sensitivity CRP, improved endothelial function and statins' safety in children. The American Heart Association (AHA) scientific statement on KD published in 2017 suggests that empirical treatment with low-dose statin may be considered for KD patients with past or current aneurysms, regardless of age or sex.

However, the current clinical data about the use of statins in KD children is still very rare. The published researches mainly focused on the endothelial function of peripheral arteries but the effects of statins on CAs and cardiac events have not been included. Therefore, more studies are needed to conform statins' feasibility and safety in children and its clinical application value.

In this study, we will recruit KD children complicated with severe CA abnormalities. These children will be given statins for one year besides other routine treatments. The coronary assessments, clinical and laboratory indexes will be followed up to study the effects of statins on long-term chronic inflammation, CA abnormalities and clinical cardiac events. At the same time, the clinical and laboratory indexes correlated to the side-effects will be monitored regularly to investigate the feasibility and safety of statins in KD children.

Eligibility criteria: Inclusion Criteria:

* \>3 months after the onset of KD currently complicated with severe coronary artery abnormalities (medium coronary aneurysms or more severe) The follow-up can be achievable All included children's guardian are required to sign the informed consent form

Exclusion Criteria:

* The KD children currently complicated with mild coronary artery abnormalities (small aneurysms or only dilation) The children's age \<2 ys The children's guardian don't agree to sign the informed consent

Primary outcomes:
measure: Change of coronary artery abnormalities measured by echocardiography
timeFrame: At baseline and one year after taking statin
Secondary outcomes:
measure: Change of LDL-C
timeFrame: At baseline and one year after taking statin
measure: Change of high-sensitivity C reactive protein (hsCRP)
timeFrame: At baseline and one year after taking statin
measure: Assessment of myocardial ischemia
timeFrame: At baseline and one year after taking statin
measure: Incidence of new-onset cardiovascular events
timeFrame: One year after taking statin
measure: Incidence of side-effects of statin in KD children
timeFrame: At baseline, 3, 6, 9 months and one year after taking statins
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Children's Hospital of Fudan University
state: Shanghai
Study officials:
affiliation: Children's Hospital of Fudan University
name: Fang Liu, MD
role: STUDY_DIRECTOR
References: